Hidradenitis
The inflammation of a sweat gland (usually of the apocrine type). The condition can be idiopathic or occur as a result of or in association with another underlying condition. Neutrophilic eccrine hidradenitis is a relatively rare variant that has been reported in patients undergoing chemotherapy, usually for non-Hodgkin lymphomas or leukemic conditions.
Subtype terms (1)
More specific conditions that are subtypes of Hidradenitis in the MeSH hierarchy.
- Hidradenitis Suppurativa
88 drugs (44 approved, 44 experimental)
Drugs by status
Phase 2 trials (3)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (36)
- Incyte
- Abbott
- Celgene
- Bausch Health Companies
- AstraZeneca
- Eli Lilly
- Pfizer
- Bayer
- ChemoCentryx
- InflaRx GmbH
- XBiotech, Inc.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Pennsylvania
- University of Pittsburgh
- Florida Academic Dermatology Centers
- University of Groningen
- University of Athens
- University of Bern
- University of Zurich
- University of California, San Diego
- University of California, San Francisco
- University of Colorado, Denver
- Icahn School of Medicine at Mount Sinai
- Covance
- University of Amsterdam
- Hellenic Institute for the Study of Sepsis
- Dermatologisk Afdeling, Roskilde, Denmark
- Dessau Medical Center
- Dermato-verenologisk afdeling S, Denmark
- Ruhr University Bochum
- +6 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (6)